Clinical Trials Directory

Trials / Unknown

UnknownNCT05310383

Tislelizumab and Radiotherapy for Recurrent Cervical Cancer

Combination of Immune Checkpoint Inhibitors Tislelizumab and Radiotherapy for Recurrent, Metastatic and Persistent Advanced Cervical Cancer: A Single-arm, Single-center, Phase 2 Clinical Study

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
58 (estimated)
Sponsor
Lei Li · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study is a prospective, multicenter, phase II clinical trial to evaluate the efficacy and safety of albumin-bound paclitaxel plus bevacizumab for platinum-resistant recurrent epithelial ovarian cancer. Patients with platinum-resistant recurrent ovarian cancer who meet the inclusion criteria, and don't meet any of the exclusion criteria, are enrolled in the study. They will receive albumin-bound paclitaxel (260 mg/m2) and bevacizumab (7.5mg/kg) intravenously every 21 days. The total treatment periods are no more than 6 cycles. Treatment continue until disease progression, intolerable toxicity, or patient refusal. Objective response rates primary objective. Progression-free survival, overall survival, and safety are secondary objectives. The study will enroll a total of 50 patients.

Conditions

Interventions

TypeNameDescription
COMBINATION_PRODUCTTislelizumab plus radiotherapyDuring the period of radiotherapy, patients receiveTislelizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W). Tislelizumab 200mg q3W was administered for up to 35 cycles (up to approximately 2 years) after radiotherapy until disease progression or toxicity.

Timeline

Start date
2022-03-27
Primary completion
2023-03-27
Completion
2024-03-27
First posted
2022-04-04
Last updated
2022-04-11

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05310383. Inclusion in this directory is not an endorsement.